Recent Updates
Recently added Catalysts
IVVD Positive Sentiment

Invivyd to Host Conference Call to Announce Results from Interim Analysis of Phase 3 DECLARATION Clinical Trial on November 23, 2026

Key Takeaway: Invivyd, Inc. will host a conference call on November 23, 2026, to discuss interim results from its Phase 3 DECLARATION clinical trial. The call is scheduled for 8:30 a.m. ET, with a press release to be issued at 7:00 a.m. ET. VYD2311, the focus of the trial, is a monoclonal antibody candidate for COVID-19.

Market Sentiment Analysis

POSITIVE FACTORS

  • Invivyd will announce interim results from a Phase 3 trial.
  • VYD2311 is designed for COVID-19 treatment and prevention.
  • The company has a strong pipeline of antibody candidates.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+20%
120-day peak, hindsight
Typical move
6.3%
average across 2 past catalysts
Cash runway
~12 mo
Medium dilution risk
Lead asset
VYD2311
Phase 3 · COVID-19

Full Press Release Details

NEW HAVEN, Conn., Nov. 22, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will host an investor call to announce results from an interim analysis of the ongoing Phase 3 DECLARATION clinical trial on Monday, November 23, 2026 at 8:30 a.m. ET. Invivyd will issue a press release regarding the results at approximately 7:00 a.m. ET that morning.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
About VYD2311 VYD2311 is a novel monoclonal antibody (mAb) candidate being developed for COVID-19 to continue to address the urgent need for new prophylactic and therapeutic options. The pharmacokinetic profile and antiviral potency of VYD2311 may offer the ability to deliver clinically meaningful titer levels through more patient-friendly means such as an intramuscular route of administration.
VYD2311 was engineered using Invivyd’s proprietary integrated technology platform and is the product of serial molecular evolution designed to generate an antibody optimized for neutralizing contemporary virus lineages. VYD2311 leverages the same antibody backbone as pemivibart, Invivyd’s investigational mAb granted emergency use authorization in the U.S. for the pre-exposure prophylaxis (PrEP) of symptomatic COVID-19 in certain immunocompromised patients, and adintrevimab, Invivyd’s investigational mAb that has a robust safety data package and demonstrated clinically meaningful results in global Phase 2/3 clinical trials for the prevention and treatment of COVID-19.

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Media Relations (781) 208-0160 media@invivyd.com

Investor Relations (781) 208-1747 investors@invivyd.com

Frequently Asked Questions

When will Invivyd announce the trial results?

Invivyd will announce the results on November 23, 2026.

What is VYD2311 used for?

VYD2311 is a monoclonal antibody candidate for COVID-19.

How can I listen to the conference call?

Listeners can register for the webcast via the provided link.

What time is the conference call scheduled?

The call is scheduled for 8:30 a.m. ET on November 23, 2026.

Last updated: Nov 22, 2026